WO1996022780B1 - Procedes d'amelioration de l'activite therapeutique de medicaments non steroides anti-inflammatoires (nsaids) et compositions de phospholipides zwitterioniques utiles a ces fins - Google Patents
Procedes d'amelioration de l'activite therapeutique de medicaments non steroides anti-inflammatoires (nsaids) et compositions de phospholipides zwitterioniques utiles a ces finsInfo
- Publication number
- WO1996022780B1 WO1996022780B1 PCT/US1996/000633 US9600633W WO9622780B1 WO 1996022780 B1 WO1996022780 B1 WO 1996022780B1 US 9600633 W US9600633 W US 9600633W WO 9622780 B1 WO9622780 B1 WO 9622780B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medicament
- phospholipid
- inflammatory agent
- steroidal anti
- zwitterionic
- Prior art date
Links
- 150000003904 phospholipids Chemical class 0.000 title claims abstract 28
- 239000000203 mixture Substances 0.000 title claims abstract 10
- 229940067631 Phospholipids Drugs 0.000 title claims abstract 4
- 230000002708 enhancing Effects 0.000 title 1
- 230000001225 therapeutic Effects 0.000 title 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract 27
- 239000003814 drug Substances 0.000 claims abstract 24
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 claims abstract 11
- 230000001754 anti-pyretic Effects 0.000 claims abstract 11
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 claims abstract 11
- KILNVBDSWZSGLL-KXQOOQHDSA-N Dipalmitoylphosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims abstract 8
- 230000000202 analgesic Effects 0.000 claims abstract 6
- 230000003110 anti-inflammatory Effects 0.000 claims abstract 5
- 230000001264 neutralization Effects 0.000 claims abstract 5
- 229940079593 drugs Drugs 0.000 claims abstract 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 12
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 11
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 6
- 150000002632 lipids Chemical class 0.000 claims 5
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical group OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 5
- 229960001860 salicylate Drugs 0.000 claims 5
- 229960000905 Indomethacin Drugs 0.000 claims 3
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 3
- 239000002221 antipyretic Substances 0.000 claims 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 3
- 229960001259 diclofenac Drugs 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 229960002009 naproxen Drugs 0.000 claims 3
- 230000000144 pharmacologic effect Effects 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 210000001772 Blood Platelets Anatomy 0.000 claims 2
- 229950004257 Ristocetin Drugs 0.000 claims 2
- 108010081391 Ristocetin Proteins 0.000 claims 2
- 230000004931 aggregating Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- VUOPFFVAZTUEGW-FBMDODLCSA-N ristocetin Chemical compound C=1C([C@@H]2C(=O)N[C@@H]([C@@H](C3=CC=C(C=C3)OC=3C=C4C=C(C=3O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](COC5[C@@H]([C@H](O)[C@@H](O)[C@H](C)O5)O)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](CO)O3)O[C@H]3[C@H]([C@H](O)[C@H](O)CO3)O)OC3=CC=C(C=C3)[C@@H](O)[C@@H]3C(=O)N[C@@H](C=5C=C(C(=C(O)C=5)C)OC=5C(O)=CC=C(C=5)[C@@H](N)C(=O)N3)C(=O)N[C@H]4C(=O)N2)O[C@H]2O[C@@H](C)[C@H](O)[C@H](N)C2)C(=O)N[C@@H](C2=CC(O)=C3)C(=O)OC)=CC=C(O)C=1C2=C3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O VUOPFFVAZTUEGW-FBMDODLCSA-N 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002349 favourable Effects 0.000 claims 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 230000002496 gastric Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000000622 irritating Effects 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
Abstract
L'invention concerne des compositions comprenant des médicaments anti-inflammatoires non stéroïdes (NSAIDs) complexés avec des phospholipides zwitterioniques neutres, ou bien présentant en même temps des effets d'irritation gastrointestinale réduits et une meilleure activité antipyrétique, analgésique et anti-inflammatoire. L'invention se rapporte également à des procédés d'utilisation de ces complexes pour traiter la fièvre, les inflammations et prévenir l'agrégation plaquettaire. Dans certains modes de réalisation, l'activité antipyrétique de dosages sous-thérapeutiques des NSAIDs est améliorée de façon à obtenir une activité antipyrétique in vivo lorsqu'elle est associée (de manière non covalente) à des phospholipides zwitterioniques, tels que dipalmitoylphosphatidylcholine.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT96902157T ATE218872T1 (de) | 1995-01-27 | 1996-01-24 | Verfahren zur erhöhung der therapeutischen wirkung von nsaids und dazu verwendbare zwitterionische phospholipidhaltige zusammensetungen |
| DE69621773T DE69621773T2 (de) | 1995-01-27 | 1996-01-24 | Verfahren zur erhöhung der therapeutischen wirkung von nsaids und dazu verwendbare zwitterionische phospholipidhaltige zusammensetungen |
| EP96902157A EP0805684B1 (fr) | 1995-01-27 | 1996-01-24 | Procedes d'amelioration de l'activite therapeutique de medicaments non steroides anti-inflammatoires (nsaids) et compositions de phospholipides zwitterioniques utiles a ces fins |
| DK01128271T DK1214940T3 (da) | 1995-01-27 | 1996-01-24 | Fremgangsmåder til at foröge den terapeutiske aktivitet af NSAIDs og sammensætninger af zwitterioniske phospholipider anvendt heri |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37969595A | 1995-01-27 | 1995-01-27 | |
| US08/379,695 | 1995-01-27 | ||
| US08/440,417 | 1995-05-12 | ||
| US08/440,417 US5763422A (en) | 1995-01-27 | 1995-05-12 | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1996022780A1 WO1996022780A1 (fr) | 1996-08-01 |
| WO1996022780B1 true WO1996022780B1 (fr) | 1996-09-19 |
Family
ID=27008731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/000633 WO1996022780A1 (fr) | 1995-01-27 | 1996-01-24 | Procedes d'amelioration de l'activite therapeutique de medicaments non steroides anti-inflammatoires (nsaids) et compositions de phospholipides zwitterioniques utiles a ces fins |
Country Status (5)
| Country | Link |
|---|---|
| EP (2) | EP0805684B1 (fr) |
| AT (1) | ATE218872T1 (fr) |
| DE (1) | DE69621773T2 (fr) |
| ES (1) | ES2176435T3 (fr) |
| WO (1) | WO1996022780A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL127143A0 (en) | 1998-11-19 | 1999-09-22 | Dpharm Ltd | Phospholipid terivatives of non-steroidal anti inflammatory drugs |
| SI1343529T1 (sl) * | 2000-12-19 | 2009-04-30 | Univ Texas | NSAID formulacije, ki vsebujejo lecitinska olja, za zaščito gastrointestinalnega trakta in zagotovitev povečanja terapevtske aktivnosti |
| US20040077604A1 (en) | 2001-12-19 | 2004-04-22 | Lenard Lichtenberger | Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| CA2534241C (fr) * | 2003-07-31 | 2012-05-29 | The Board Of Regents Of The University Of Texas System | Compositions et methodes permettant de traiter, de prevenir et/ou d'attenuer des cancers, l'apparition de cancers ou les symptomes de cancers |
| AU2009290712A1 (en) | 2008-09-09 | 2010-03-18 | Astrazeneca Ab | Method for delivering a pharmaceutical composition to patient in need thereof |
| AU2010263304A1 (en) | 2009-06-25 | 2012-02-02 | Astrazeneca Ab | Method for treating a patient at risk for developing an NSAID-associated ulcer |
| KR102180667B1 (ko) | 2011-09-29 | 2020-11-20 | 피엘엑스 옵코 인코포레이티드 | 위장관을 따라 약물을 표적화 방출하기 위한 pH 감응성 담체, 그로부터의 조성물, 및 이들의 제조 및 사용 방법 |
| CA2860231A1 (fr) | 2011-12-28 | 2013-07-04 | Pozen Inc. | Compositions et procedes d'administration d'omeprazole plus acide acetylsalicylique ameliores |
| US20130281405A1 (en) * | 2012-04-02 | 2013-10-24 | Lenard M. Lichtenberger | Use of pc-nsaids to treat and/or prevent pulmonary inflammation |
| JP2023518822A (ja) | 2020-03-26 | 2023-05-08 | ピーエルエックス オプコ インコーポレイテッド | ｐＨ依存的再構築が可能な医薬キャリア、その製造方法及び使用方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4369182A (en) * | 1978-09-27 | 1983-01-18 | A. Nattermann & Cie Gmbh | Inflammation-preventing pharmaceutical composition of oral administration |
| US4421747A (en) * | 1978-12-27 | 1983-12-20 | A. Nattermann & Cie. Gmbh | Inflammation-preventing pharmaceutical composition of oral administration |
| DE2914789A1 (de) * | 1979-04-11 | 1980-10-16 | Nattermann A & Cie | Injizierbare arzneimittel mit entzuendungshemmender wirkung |
| DE2914788A1 (de) * | 1979-04-11 | 1980-10-16 | Nattermann A & Cie | Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung |
| DE2951142C2 (de) * | 1979-12-19 | 1983-11-03 | A. Nattermann & Cie GmbH, 5000 Köln | Suppositorium-Zubereitung von Indometacin oder Acemetacin |
| JP2844756B2 (ja) * | 1989-12-01 | 1999-01-06 | 日本新薬株式会社 | 脂肪乳剤 |
| JP3280071B2 (ja) * | 1992-05-27 | 2002-04-30 | ポーラ化成工業株式会社 | 消炎鎮痛外用剤 |
-
1996
- 1996-01-24 DE DE69621773T patent/DE69621773T2/de not_active Expired - Lifetime
- 1996-01-24 AT AT96902157T patent/ATE218872T1/de not_active IP Right Cessation
- 1996-01-24 ES ES96902157T patent/ES2176435T3/es not_active Expired - Lifetime
- 1996-01-24 EP EP96902157A patent/EP0805684B1/fr not_active Expired - Lifetime
- 1996-01-24 EP EP01128271A patent/EP1214940B1/fr not_active Expired - Lifetime
- 1996-01-24 WO PCT/US1996/000633 patent/WO1996022780A1/fr active Search and Examination
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vane et al. | Mechanism of action of nonsteroidal anti-inflammatory drugs | |
| US4369182A (en) | Inflammation-preventing pharmaceutical composition of oral administration | |
| US4309421A (en) | Stabilized parenterally administrable solutions | |
| US4332795A (en) | Inflammation-preventing pharmaceutical composition of oral administration | |
| WO1996022780B1 (fr) | Procedes d'amelioration de l'activite therapeutique de medicaments non steroides anti-inflammatoires (nsaids) et compositions de phospholipides zwitterioniques utiles a ces fins | |
| US5955451A (en) | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein | |
| US4421747A (en) | Inflammation-preventing pharmaceutical composition of oral administration | |
| Charrois et al. | Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer | |
| US20080213351A1 (en) | Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease | |
| US4378354A (en) | Inflammation-preventing pharmaceutical composition of oral administration | |
| US5763422A (en) | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein | |
| JPS5823619A (ja) | リウマチ様関節炎の治療薬 | |
| Kurzrock et al. | All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. | |
| WO1997048391A2 (fr) | Methodes et compositions a base de r-ibuprofene | |
| CA2431606A1 (fr) | Methode et compositions comprenant des formulations qui contiennent des huiles de lecithine et des ains pour proteger le tractus gastro-intestinal et pour fournir une activite therapeutique amelioree | |
| GB2386836A (en) | Anti-cancer combinations | |
| WO1997048391A9 (fr) | Methodes et compositions a base de r-ibuprofene | |
| KR920703046A (ko) | 경구용 항응고제/혈소판 억제제 저용량 제형 | |
| Whittle et al. | A biochemical basis for the gastrointestinal toxicity of non-steroid antirheumatoid drugs | |
| Vane et al. | The history of anti-inflammatory drugs and their mechanism of action | |
| ES2176435T3 (es) | Procedimiento para mejorar la actividad terapeutica de medicamentos anti-inflamatorios (nsaids) y composicion de fosfolipidos dipolares utiles para tales fines. | |
| RU2001116085A (ru) | Фосфолипидные комплексы проантоцианидина а2 в качестве антиатеросклеротических агентов | |
| US4528193A (en) | Inflammation-preventing pharmaceutical composition of oral administration | |
| US5128334A (en) | Analgesic and anti-inflammatory medicine | |
| Cailleteau | Ketoprofen in dentistry: a pharmacologic review |